Virpax Pharmaceuticals, Inc. Common Stock
VRPX
VRPX was delisted on the 3rd of April, 2025.
14 hedge funds and large institutions have $2.17M invested in Virpax Pharmaceuticals, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 14 → 14 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
31% less capital invested
Capital invested by funds: $3.13M → $2.17M (-$964K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$41.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$9K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.88K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$360 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$64.8K |
| 2 |
Morgan Stanley
New York
|
-$24.5K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$19K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$7.2K |
| 5 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$720 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $1.25M | -$7.2K | -20 | -0.5% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $441K | +$41.8K | +116 | +8% |
|
|
3
Renaissance Technologies
New York
| $188K | -$64.8K | -180 | -22% |
|
4
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $120K | – | – | – |
|
5
Geode Capital Management
Boston,
Massachusetts
| $78K | – | – | – |
|
|
WAM
6
Warberg Asset Management
Winnetka,
Illinois
| $23K | -$720 | -2 | -3% |
|
7
Cambridge Investment Research Advisors
Fairfield,
Iowa
| $20K | – | – | – |
|
8
Northern Trust
Chicago,
Illinois
| $18K | – | – | – |
|
|
QPW
9
Quantum Private Wealth
Tampa,
Florida
| $11K | – | – | – |
|
|
10
UBS Group
Zurich,
Switzerland
| $7K | +$9K | +25 | New |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| $5K | +$2.88K | +8 | +80% |
|
|
12
Morgan Stanley
New York
| $1K | -$24.5K | -68 | -94% |
|
13
BlackRock
New York
| $1K | – | – | – |
|
|
14
Osaic Holdings
Scottsdale,
Arizona
| $1K | +$360 | +1 | +100% |
|
|
15
Citadel Advisors
Miami,
Florida
| – | -$19K | -46 | Closed |
|
VRPX Hedge Fund Activity: Q3 2022 in Review
14 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Virpax Pharmaceuticals, Inc. Common Stock (VRPX) for Q3 2022, worth a combined $2.17M — down 31% from $3.13M a quarter earlier.
Fund positioning in VRPX was balanced in Q3 2022: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, adding an estimated $41.8K. The largest seller was Renaissance Technologies, cutting an estimated $64.8K.
- 14 institutional investors held Virpax Pharmaceuticals, Inc. Common Stock (VRPX) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $2.17M of Virpax Pharmaceuticals, Inc. Common Stock stock for Q3 2022, down 31% quarter-over-quarter.
- 1 fund opened new Virpax Pharmaceuticals, Inc. Common Stock positions in Q3 2022 and 1 closed out, a net change of 0 holders.
- The largest Virpax Pharmaceuticals, Inc. Common Stock buyer in Q3 2022 was Vanguard Group, an estimated $41.8K added.
- The largest Virpax Pharmaceuticals, Inc. Common Stock seller in Q3 2022 was Renaissance Technologies, an estimated $64.8K sold.
Based on aggregated 13F filings for Q3 2022.